Korea Investment Corporation

Korea Investment Corporation is the sovereign wealth fund of South Korea, managing approximately $200 billion in assets across global public equities, fixed income, alternatives, and direct private investments. KIC is not a venture fund in any traditional sense; it is a large institutional allocator that commits capital to top-tier global venture, growth, and private equity funds, and selectively co-invests alongside those managers in late-stage and growth equity rounds. Healthcare exposure exists primarily through fund commitments to healthcare-specialist managers and selective co-investments in late-stage healthcare companies, with check sizes for direct co-investments generally $25M to $100M. Founders should not approach KIC as a primary venture investor; the entry path runs through KIC’s portfolio fund managers rather than direct outreach. Founders best suited for any direct KIC capital are growth and late-stage CEOs with $50M-plus revenue or compelling biotech platforms, who are raising $100M-plus rounds led by a top-tier financial investor that has a relationship with KIC. Founders who do not fit include any team earlier than late Series C or D, pre-revenue biotech without a strong financial lead, and capital-light businesses. Geographic preference is global with selective Korean strategic angles. The entry path for any direct co-investment is through the financial lead investor’s KIC relationship, not direct outreach. Founders should focus their time on the lead investor rather than KIC, and expect any KIC participation to come through a syndicated structure rather than a direct relationship.